SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Goldman Sachs upgrade to Buy, citing Palantirs sovereign-AI and customized-software opportunities, helped fuel a breakout to fresh highs. Traders largely celebrated the momentum and speculated about short covering, while bears warned that the rally has pushed the valuation too far.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflakes agentic AI marketplace launch and bullish analyst coverage are drawing attention, reinforcing optimism that AI demand can accelerate its data-cloud business as shares rally toward recent highs. Traders are debating whether the move signals a sustained breakout or leaves the stock overvalued after its sharp run-up.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile shares plunged after SpaceX agreed to acquire nationwide 800 MHz spectrum, raising concerns that Starlink Mobile could become a longer-term wireless competitor. Traders are split between seeing a lasting competitive threat and calling the selloff an overreaction, given SpaceX still needs to prove its network and build out infrastructure while T-Mobile has an established customer base and network.

Nasdaq, Inc. is a holding company, which engages in trading, clearing, exchange technology, regulatory, securities listing, information, and public and private company services. It operates through the following segments: Capital Access Platforms, Financial Technology, and Market Services. The Capital Access Platforms segment delivers liquidity, transparency, and integrity to the corporate issuer and investment community by empowering clients to effectively navigate the capital markets, achieve their sustainability goals, and drive governance excellence. The Financial Technology segment offers platforms that improve the liquidity, transparency, and integrity of the global economy by architecting and operating the markets. The Market Services segment includes equity derivative trading and clearing, cash equity trading, fixed income, currency, and commodities trading. The company was founded by Gordon S. Macklin in 1971 and is headquartered in New York, NY.

Nasdaq Inc

Discussion is fragmented, with traders debating NDAQs technical direction and broader market moves. A recurring company-specific topic is Nasdaqs push toward near-continuous trading and tokenized equities, viewed by some as a potential growth opportunity and by others with concern about the risks.

Verizon Communications, Inc. is a holding company, which engages in the provision of communications, information, and entertainment products and services. It operates through the following business segments: Consumer and Business. The Consumer segment provides consumer-focused wireless and wire line communications services and products. The Business segment offers wireless and wireline communications services and products, including FWA broadband, data, video and conferencing services, corporate networking solutions, security and managed network services, local and long-distance voice services, and network access to deliver various IoT services and products. The company was founded in 1983 and is headquartered in New York, NY.

Verizon Communications Inc

Verizon Communications Inc.

Verizon shares sold off amid concerns that SpaceXs low-band spectrum acquisition could help Starlink Mobile compete with established wireless carriers. Traders are divided between viewing the move as a long-term threat and calling the selloff premature or overdone given the infrastructure and time needed to build a competing network; some see the drop as a buying opportunity.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

AMRN is drawing attention amid a steep slide toward 52-week lows, prompting frustration over management and debate about the companys value despite its cash position and international growth. Traders are also focused on the pending Phase 3 EMT-2 results and LR-EtEPA patent, with bullish speculation about their potential weighed against uncertainty about the data, patent prospects, and how either could translate into commercial value.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas sharp selloff is the main focus, with traders debating whether shares left over after the substantial issuer bid are adding selling pressure; some also point to shorting and elevated fuel costs. Bullish holders argue the buyback and Aeroplans value support the stock, while critics question managements timing and the airlines investment outlook.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs rally and elevated volume are drawing attention to Starknets privacy and Bitcoin DeFi push, including shielded asset features, alongside its post-quantum security narrative. Many traders are bullish on the technology and ecosystem activity, while others remain cautious about token unlocks, dilution, and whether the price move will hold.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a sharp breakout to fresh highs alongside strength in software stocks. Bulls point to momentum and demand for AI observability, while bears warn that the valuation is stretched and see risk of a technical reversal.

Valero Energy Corp. engages in the manufacture and marketing of transportation fuels and other petrochemical products. It operates through the following business segments: Refining, Ethanol and Renewable Diesel. The Refining segment consists of refining operations, associated marketing activities, and logistics assets that support its refining operations. The Ethanol segment includes its ethanol operations, associated marketing activities, and logistics assets that support its ethanol operations. The Renewable Diesel covers the operations of Diamond Green Diesel Holdings LLC. The company was founded in 1980 and is headquartered in San Antonio, TX.

Valero Energy Corp.

Valero is drawing attention as tight fuel supplies and unusually strong diesel refining margins support the refiner trade, alongside analyst target changes. Traders are split between citing robust margins as a reason for continued strength and warning that the sharp rally looks overextended, with profit-taking and bearish bets also discussed.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround 

X4 Pharmaceuticals (XFOR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

X4 Pharmaceuticals (XFOR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial

(RTTNews) - X4 Pharmaceuticals (XFOR) announced positive outcome of Type C Meeting with the
FDA related to the global 4WARD Phase 3 clinical trial. The purpose of the meeting was to gain alignment on a revised sample size and associated statistical power and the size of the safe...

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now

Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now...

X4 Pharmaceuticals (NASDAQ:XFOR) Issues Earnings Results

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.04. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative...

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

X4 Pharmaceuticals Inc

X4 Pharma To Halve Headcount Amid Efforts To Complete Neutropenia Trial

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$XFOR I posted a big piece on this before. This company today is fundamentally different vs. pre-2025 - and that starts with leadership.

Paula Ragan (CEO) and Adam Mostafa (CFO)
“Stepped down”, and the company has since shifted direction with a team that brings prior $CTIC experience. I discuss the successes of this new team in a post on my X account.

That change is central to the thesis.

Latest guidance reinforces the setup:
• Cash runway through 2028 (no near-term dilution pressure)
• Phase 3 (4WARD) enrollment on track for Q3
2026
• EU decision expected Q2 2026 (following positive opinion)
• Commercial launch underway (early revenue ramp)

In short: funded, progressing, and building.

The upside case hinges on mavorixafor — particularly in chronic neutropenia (CN), where it has potential to become a meaningful (even blockbuster) asset.

This is no longer the same risk profile the market is anchoring to.

Investor Gadget

$XFOR secured a $150M term loan agreement with K2 HealthVentures, funding an $80M tranche to repay existing debt.

Feed

News

Sentiment

Earnings

Fundamentals

Info

XFOR X4 Pharmaceuticals Inc

Fundamentals

Latest XFOR News